JPMorgan and Barclays Finance AMRI’s Acquisition of Euticals

May 05, 2016

NEW YORK – Paul Hastings LLP, a leading global law firm, is representing JPMorgan and Barclays as the committed debt financing providers and lead arrangers in connection with AMRI’s definitive agreement to acquire all outstanding shares of Prime European Therapeuticals S.p.A., also known as "Euticals", in a transaction valued at approximately $358 million (EUR 315 million), consisting of shares of AMRI common stock, cash, and seller notes.

Euticals is a privately-held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). It operates a network of API facilities primarily in Italy, Germany, U.S. and France.
The Paul Hastings team was led by Leveraged Finance partner John Cobb, with assistance from London partner Luke McDougall and associates Joe Fastiggi, Julie Park and Sean Murray.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.